Topoisomerase II as a target of antileukemic drugs.
The identification of topoisomerase II as a target of antineoplastic drug therapy is traced from the original observations by Ross et al. (1,2) in murine leukemia cells through studies with m-AMSA-resistant human leukemia cells. Recently developed quantitative biochemical assays of topoisomerase II activity and the susceptibility of topoisomerase II to the effects of m-AMSA have allowed the principles identified in murine and human leukemia cell culture systems to be applied to clinical material; a prospective trial is testing the utility of such assays for individualizing antineoplastic drug therapy.
Zwelling
L A
LA
Estey
E
E
Bakic
M
M
Silberman
L
L
Chan
D
D
D000677:Amsacrine / Q000627:therapeutic use*; D000818:Animals; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004351:Drug Resistance; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000201:enzymology; D051379:Mice
D000677:Amsacrine; D004250:DNA Topoisomerases, Type II